NEW YORK, March 10, 2017 /PRNewswire/ --
Stock-Callers.com have issued research reports by Bioverativ Inc. (NASDAQ:BIVV), Pulmatrix Inc. (NASDAQ: PULM), PharmAthene Inc. (NYSEMKT: PIP), and Zosano Pharma Corp. (NASDAQ: ZSAN). On March 06th, 2017, Oppenheimer issued a note expressing optimism on the entire Biotech sector. As
Waltham, Massachusetts headquartered Bioverativ Inc.'s shares rose 1.34%, closing Thursday's trading session at $53.57. The stock recorded a trading volume of 967,354 shares. Shares of the Company, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have advanced 20.54% in the last month and 19.10% since the start of this year. Additionally, Bioverativ's stock is trading 12.36% above its 50-day moving average and 12.36% above its 200-day moving average.
On February 28th, 2017, research firm Piper Jaffray upgraded the Company's stock rating from 'Neutral' to 'Overweight' while revising its previous target price from $44 a share to $65 a share.
On March 02nd, 2017, Bioverativ and Swedish Orphan Biovitrum AB announced that interim results from the B-YOND extension trial, which studies ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in previously-treated subjects with severe hemophilia B, were published in the March 2017 issue of Thrombosis and Haemostasis. The study results reinforce the long-term safety and efficacy of prophylactic treatment with ALPROLIX over a median duration of more than three years in adults/adolescents and more than a year and a half in children under 12 years of age. The primary outcome measure was development of inhibitors; no patients treated with ALPROLIX in the study developed inhibitors. See our free and comprehensive research report on BIVV at:
On Thursday, shares in Lexington, Massachusetts headquartered Pulmatrix Inc. recorded a trading volume of 372,751 shares. The stock declined 1.41%, ending the day at $3.50. The Company's shares have skyrocketed 463.88% in the previous three months and 493.22% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 32.34% and 86.95%, respectively. Furthermore, shares of Pulmatrix, which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, have an RSI of 49.40.
On February 03rd, 2017, Pulmatrix announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $3.33 million of shares of common stock in a registered direct offering. The Company agreed to sell an aggregate of approximately 950,000 shares of common stock, at a price of $3.50 per share, in the registered direct offering. PULM free research report PDF is just a click away at:
Annapolis, Maryland headquartered PharmAthene Inc.'s stock edged 22.09% higher, finishing the day at $0.88. A total volume of 10.74 million shares was traded, which was above their three months average volume of 4.31 million shares. The Company's shares are trading below their 50-day moving average by 60.96%. Additionally, shares of PharmAthene, which develops and commercializes medical counter measures against biological and chemical threats in the US, have an RSI of 32.97. Sign up for your complimentary report on PIP at:
Shares in Fremont, California headquartered Zosano Pharma Corp. ended yesterday's session 6.22% higher at $2.39. The stock recorded a trading volume of 730,722 shares. The Company's shares have surged 102.54% in the last one month, 191.46% over the previous three months, and 206.41% since the start of this year. The stock is trading 51.93% and 102.83% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Zosano Pharma, which develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications, have an RSI of 55.24.
On March 01st, 2017, Zosano reported net loss for full year 2016 of $29.8 million, or $2.17 per share, compared with a net loss of $28.4 million, or $2.49 per share, for full year 2015. The Company's net loss for Q4 2016 was $7.7 million, or $0.46 per share, compared with a net loss of $7.6 million, or $0.64 per share, for Q4 2015. Total revenue for the full year 2016 was zero, compared with $0.3 million in 2015. Zosano had no revenue for Q4 2016 and Q4 2015. As of December 31, 2016, Zosano had cash and cash equivalents of $15.0 million. Register for free on Stock-Callers.com and download the latest research report on ZSAN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All